期刊文献+

冠心病患者的氯吡格雷应用剂量研究 被引量:4

下载PDF
导出
摘要 目的研究应用氯吡格雷不同剂量的冠心病患者血清sCD40L水平的变化情况。方法选取我院经确诊的冠心病患者345例,其中稳定型心绞痛(SAP)患者211例,非ST段抬高型急性冠状动脉综合征(NST-ACS)患者134例,采用随机的方式,将稳定型心绞痛(SAP)患者分为SAP1组105例、SAP2组106例,氯吡格雷剂量分别为75和150mg·d-1;非ST段抬高型急性冠状动脉综合征(NST-ACS)患者均分为NST-ACS1组、NST-ACS2组,氯吡格雷负荷量均为300mg,维持量分别为75和150mg·d-1。对冠心病患者分别于用药前、服用氯吡格雷负荷量24h、服用氯吡格雷120h取静脉血,测定血清sCD40L的质量浓度;选取健康人员50名作为对照组,不给予药物干预,同期取血样作对比研究。结果 (1)冠心病(SAP组、NST-ACS组)患者血清sCD40L的质量浓度均高于对照组(P<0.05);相对SAP组,NST-ACS组血清sCD40L的质量浓度较高(P<0.05)。(2)相对用药前,SAP组用药120h血清sCD40L的质量浓度明显下降(P<0.05),且SAP1、SAP22组组间血清sCD40L的质量浓度无明显差异(P>0.05)。(3)相对用药前,NST-ACS组服用氯吡格雷负荷量24h血清sCD40L的质量浓度明显下降(P<0.05);NST-ACS组用药120h血清sCD40L的质量浓度明显下降(P<0.05),且NST-ACS1、NST-ACS22组组间血清sCD40L的质量浓度无明显差异(P>0.05)。结论相对健康人群,冠心病患者血清sCD40L的质量浓度较高,氯吡格雷能有效地降低冠心病患者血清sCD40L的质量浓度。
作者 陈磊
出处 《西北药学杂志》 CAS 2015年第4期418-419,共2页 Northwest Pharmaceutical Journal
  • 相关文献

参考文献7

二级参考文献72

  • 1《中国成人血脂异常防治指南》制订联合委员会.中国成人血脂异常防治指南[M].北京:人民卫生出版社,2007:16-17.
  • 2Navarese EP, Verdoia M, Schaffer A, et al. Ischaemic and bleeding complications with new, compared to standard, ADP- antagonist regimens in acute coronary syndromes: a meta-analy- sis of randomized trials. QJM, 2011,104 : 561-569.
  • 3Frelinger AL 3rd, Michelson AD, Wiviott SD, et al. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasug- rel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. Thromb Haemost, 2011,106 : 219-226.
  • 4Jung JH, Min PK, Lee SH, et al. Clopidogrel pretreatment be- fore primary percutaneous coronary stenting in patients with acute ST-segment elevation myocardial infarction: comparison of high loading dose (600 rag) versus low loading dose (300 mg). Coron Artery Dis, 2009,20 : 150-154.
  • 5Levine GN, Bates ERr Blankenship JC, et al. 2011 ACCF/AHA/ SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foun- dation/American Heart Association Task Force on Practice Guide- lines and the Society for Cardiovascular Angiography and Inter- ventions. Catheter Cardiovasc Interv, 2012,79 : 453-495.
  • 6Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization. Eur Heart J, 2010,31 : 2501-2555.
  • 7Price M J, Berger PB, Teirstein PS, et al. Standard- vs high- dose clopidogrel based on platelet function testing after percuta- neous coronary intervention: the GRAVITAS randomized trial. JAMA, 2011,305 : 1097-1105.
  • 8Bonello L, Berbis J, Laine M, et al. Biological efficacy of a 600 mg loading dose of clopidogrel in ST-elevation myocardial infarc- tion. Thromb I-Iaemost, 2012,108 : 101-106.
  • 9Gachet C. Regulation of platelet functions by P2 receptors. Annu Rev Pharmacol Toxicol, 2006, 46:277-300.
  • 10Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST- elevation myocardial infarction (updating the 2004 guideline and 2007 focused update ) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update ) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2009, 54:2205-2241.

共引文献118

同被引文献39

引证文献4

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部